Erbitux cetuximab: Phase III started

MRK began a Phase III trial of Erbitux as an adjuvant to treat colon cancer. IMCL and BMY market Erbitux for metastatic colorectal cancer and advanced squamous cell carcinoma of the head and neck (SCC...